Drugs / GSK-294
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03567499 | Jul 2018 → May 2019 | amyloidosis | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02603172 | May 2016 → May 2017 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK-294 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068552 ↗ |
| Known as | GSK3039294 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03567499 ↗ |
| Action | Deplete | “for plasma serum amyloid P component (SAP) depletion” NCT02603172 ↗ |
| Modality | Small molecule | — CHEMBL6068552 ↗ |
| Route | Oral | “will be taken orally with water.” NCT02603172 ↗ |